Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Teniposide Pregnancy and Breastfeeding Warnings

Teniposide is also known as: Vumon

Medically reviewed on Aug 6, 2018

Teniposide Pregnancy Warnings

Teniposide has been assigned to pregnancy category D by the FDA. Animal studies have revealed evidence of embryotoxicity, teratogenicity reduced sperm count and genetic damage to sperm.. There are no controlled data in human pregnancy. Teniposide should only be given during pregnancy when there are no alternatives and benefit outweighs risk. Women of childbearing potential should be advised to avoid becoming pregnant during therapy with teniposide. Young men of reproductive age should be advised of the possibility of compromised ability to father a child and a possibility for birth defects if they do. They should also be advised of the option to store sperm for future artificial insemination.

See references

Teniposide Breastfeeding Warnings

There are no data on the excretion of teniposide into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Vumon (teniposide)." Bristol-Myers Squibb, Princeton, NJ.

References for breastfeeding information

  1. "Product Information. Vumon (teniposide)." Bristol-Myers Squibb, Princeton, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide